Posts in category Economic Times
Ambuja Cements shares in focus ahead of Q2 earnings today. Here’s what to expect (28-10-2024)
Ambuja Cements’ shares are set to be a focus as the company announces its Q2 earnings. Expected are a 43%-61% YoY profit drop and flat to 3% decline in revenue. Forecasts suggest lower PAT, EBITDA, and EBITDA margin due to weak realisations and price weakness.
CDMO is the biggest theme; select companies can grow 5 times in next 10 years: Madhusudan Kela (28-10-2024)
Geopolitical tensions between the US and China are pushing contract manufacturing business to India. Madhusudan Kela believes that the Contract Development & Manufacturing Organization (CDMO) sector could grow five-fold in the next decade. He emphasizes the importance of flexibility and having an open mind in investment strategies, highlighting the significance of climate change and remembering influential market figures.
These 4 stocks close crossing below VWAP on October 25 (28-10-2024)
When the closing price falls below the VWAP, it signifies that the closing price is lower than the average price at which it was traded throughout the day, with the average being weighted by trading volume
ICICI Bank shares in focus on 14% YoY jump in Q2 net profit (28-10-2024)
ICICI Bank reported a 14.5% rise in standalone net profit to Rs 11,746 crore for the September quarter. Net interest income increased by 9.5% year-on-year, and the domestic loan portfolio grew by 15.7%. The bank’s total capital adequacy ratio stands at 16.66%, while non-interest income grew by 10.8%.
Negative Breakout: Six stocks cross below their 200 DMAs (28-10-2024)
The 200 DMA is used as a key indicator by traders for determining the overall trend in a particular stock.
Infosys’ Rs 21 interim dividend record date tomorrow. Last chance to buy (28-10-2024)
Infosys announced an interim dividend of Rs 21 per share, with October 29 as the record date. The payout date is set for November 8. Infosys reported a 5% rise in Q2 net profit to Rs 6,506 crore and revised its FY25 revenue guidance to 3.75%–4.5%.
Sun Pharma shares in focus ahead of Q2 results today (28-10-2024)
Sun Pharma Share Price: Sun Pharma is set to announce its Q2 FY25 results, with revenue growth expected to be driven by domestic business and higher specialty sales in the US. Gross margins may improve sequentially, though EBITDA margins could decline due to increased R&D spending.